Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.60 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.60 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140802 | 0.96 | TLR7 (0.57) | TLR7TLR8NUDT1 | |
| SCHEMBL1140842 | 0.94 | TLR7 (0.57) | TLR7TLR8NUDT1 | |
| SCHEMBL5159581 | 0.86 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL1141117 | 0.83 | TLR7 (0.39) | TLR7TLR8NUDT1 | |
| SCHEMBL1895996 | 0.82 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| Hydrochloric Acid SCHEMBL1141362 | 0.82 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL1141150 | 0.82 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL1140692 | 0.81 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL1140386 | 0.81 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL728616 | 0.81 | TLR7 (0.69) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | claimed |
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-8541438-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-7884207-B2 | such as 4-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol, used as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884207-B2 | such as 4-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol, used as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884207-B2 | such as 4-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol, used as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | IL2, IFNG, IL4 | TLR7 62/4885TLR8 346/4885NUDT1 221/4885 |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | TLR7 56/4885TLR8 342/4885NUDT1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.